title: Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis.
abstract: Conflicting data exist on the role of graft rejection as a risk factor for later development of accelerated graft coronary artery disease. We analyzed 126 consecutive heart transplant recipients treated with cyclosporine-based immunosuppressive regimens and devised an arbitrary method to incorporate the number, duration, and severity of myocardial rejection episodes during the first postoperative year, resulting in a rejection score for each patient. We then correlated the later incidence (mean follow-up, 4 years) of angiographic accelerated graft coronary artery disease with this rejection score and with its components: number, duration, and severity of rejection; number and duration of untreated rejection; and incidence and duration of delayed rejection therapy. Accelerated graft coronary artery disease developed in 60 patients (48%). The rejection score was 96.7 for patients in the "no accelerated graft coronary artery disease" group and 110.4 for those in the "accelerated graft coronary artery disease" group (p = NS). No significant difference was noted between patients with and without disease in any of the other seven rejection parameters analyzed, and no significant difference in time to occurrence of disease was noted between groups divided at the median rejection score. Donor age was older and fasting triglyceride blood level was higher in patients with accelerated graft coronary artery disease than in those without disease. All other clinical characteristics, including HLA mismatches, ischemic time, blood pressure, lipid profile, and drug therapy, did not differ between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Cardiovascular Medicine, Stanford University School of Medicine, CA 94305.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Gao
authors.forename: J S
authors.initials: JS
authors.lastname: Schroeder
authors.forename: S A
authors.initials: SA
authors.lastname: Hunt
authors.forename: H A
authors.initials: HA
authors.lastname: Valantine
authors.forename: I R
authors.initials: IR
authors.lastname: Hill
authors.forename: E B
authors.initials: EB
authors.lastname: Stinson
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D003327:Coronary Disease / Q000209:etiology*; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006084:Graft Rejection / Q000175:diagnosis; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D016572:Cyclosporine